Biofilm Production by Candida Species and Inadequate Antifungal Therapy as Predictors of Mortality for Patients with Candidemia
Top Cited Papers
- 1 June 2007
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 45 (6) , 1843-1850
- https://doi.org/10.1128/jcm.00131-07
Abstract
Nosocomial Candida bloodstream infections rank among infections with highest mortality rates. A retrospective cohort analysis was conducted at Catholic University Hospital to estimate the risk factors for mortality of patients with candidemia. We reviewed records for patients with a Candida bloodstream infection over a 5-year period (January 2000 through December 2004). Two hundred ninety-four patients (42.1% male; mean age ± standard deviation, 65 ± 12 years) were studied. Patients most commonly were admitted with a surgical diagnosis (162 patients [55.1%]), had a central venous catheter (213 [72.4%]), cancer (118 [40.1%]), or diabetes (58 [19.7%]). One hundred fifty-four (52.3%) patients died within 30 days. Of 294 patients, 168 (57.1%) were infected by Candida albicans, 64 (21.7%) by Candida parapsilosis, 28 (9.5%) by Candida tropicalis, and 26 (8.8%) by Candida glabrata. When fungal isolates were tested for biofilm formation capacity, biofilm production was most commonly observed for isolates of C. tropicalis (20 of 28 patients [71.4%]), followed by C. glabrata (6 of 26 [23.1%]), C. albicans (38 of 168 [22.6%]), and C. parapsilosis (14 of 64 [21.8%]). Multivariable analysis identified inadequate antifungal therapy (odds ratio [OR], 2.35; 95% confidence interval [95% CI], 1.09 to 5.10; P = 0.03), infection with overall biofilm-forming Candida species (OR, 2.33; 95% CI, 1.26 to 4.30; P = 0.007), and Acute Physiology and Chronic Health Evaluation III scores (OR, 1.03; 95% CI, 1.01 to 1.15; P < 0.001) as independent predictors of mortality. Notably, if mortality was analyzed according to the different biofilm-forming Candida species studied, only infections caused by C. albicans (P < 0.001) and C. parapsilosis (P = 0.003) correlated with increased mortality. Together with well-established factors, Candida biofilm production was therefore shown to be associated with greater mortality of patients with candidemia, probably by preventing complete organism eradication from the blood.Keywords
This publication has 40 references indexed in Scilit:
- Biofilm Formation by and Antifungal Susceptibility of Candida Isolates from UrineApplied and Environmental Microbiology, 2007
- Epidemiology of Invasive Candidiasis: a Persistent Public Health ProblemClinical Microbiology Reviews, 2007
- Time to Initiation of Fluconazole Therapy Impacts Mortality in Patients with Candidemia: A Multi‐Institutional StudyClinical Infectious Diseases, 2006
- Excess Mortality, Hospital Stay, and Cost Due to Candidemia: A Case-Control Study Using Data From Population-Based Candidemia SurveillanceInfection Control & Hospital Epidemiology, 2005
- Candida Infections of Medical DevicesClinical Microbiology Reviews, 2004
- Biofilm-Forming Ability ofCandida albicansIs Unlikely To Contribute to High Levels of Oral Yeast Carriage in Cases of Human Immunodeficiency Virus InfectionJournal of Clinical Microbiology, 2003
- Candida biofilmsCurrent Opinion in Microbiology, 2002
- Biofilm Production by Isolates of Candida Species Recovered from Nonneutropenic Patients: Comparison of Bloodstream Isolates with Isolates from Other SourcesJournal of Clinical Microbiology, 2002
- Standardized Method for In Vitro Antifungal Susceptibility Testing of Candida albicans BiofilmsAntimicrobial Agents and Chemotherapy, 2001
- CDC definitions for nosocomial infections, 1988American Journal of Infection Control, 1988